IQVIA HoldingsIQV

NYSE · USA · Segment 4 of 8 in the Medicine, pharma & life science value chain: CDMO & pharma manufacturing

Drug companies outsource clinical trials to IQVIA, and many of the same customers buy its health data and analytics. A third arm sells commercial services to the pharmaceutical industry.

CDMO & pharma manufacturing: Contract development and manufacturing of medicines, the industrial backbone behind the drugs.

Key metrics

Market cap

$39.4B

Price

$260.24

Today

+0.2%

Return YTD

+15.3%

Return 1Y

+40.1%

P/E

28.6

P/S

2.3

P/B

6.4

Data as of 2026-08-25 · updates daily after U.S. close

Theme exposure

Clinical research & dataClinical researchHealth dataPharma services

In the value chain

Products & services

Clinical trials (CRO)
Health data & analytics
Commercial pharma services

Competitors

Icon plc
PPD (Thermo Fisher)
Labcorp

Risks

Biotech funding
Data privacy regulation

Supply chain

Supplies →

PfizerPFE Merck & Co.MRK Gilead SciencesGILD BiogenBIIB United TherapeuticsUTHR Neurocrine BiosciencesNBIX Eli LillyLLY AmgenAMGN

Full supply chain for IQV →

Same segment: CDMO & pharma manufacturing

West Pharmaceutical ServicesWST Charles River LaboratoriesCRL

Compare IQV

IQV vs WST IQV vs CRL

See where IQVIA Holdings sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →